N/A N=115 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face
Age-related Volume Deficit in the Mid-face
Primary: Subject Experience Measured by Patient Satisfaction Questionnaire — 1.94; 1.62; 1.51 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=65 Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes
Dental Caries
Primary: Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours — 0.54; 0.54 ln(μg*F*minutes/cm^2) — p=0.9762
Phase 1 N=12 Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
HIV
Primary: Median Scores on a Subjective Sweet Intensity Scale for Current and New Powder for Oral Use (POU) Formulations of Atazanavir — 1.5; 1.5; 1.0 Units on a scale
Phase 2 N=110 Computer-Assisted Intervention for Smoking During Pregnancy
Smoking
Primary: Smoking Behavior (Self-report Confirmed by Expired Breath CO) — 2; 7; 2; 5 participants
Phase 3 N=91 Effects of SAMe in Patients With Alcoholic Liver Disease
Liver Disease, Alcoholic
Primary: Changes in Serum AST Levels — -13.5; -56 Units per liter (U/L)
Phase 4 N=20 Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles
Peri-oral Wrinkles
Primary: Local and Systemic Adverse Events — 100 percentage of participants
Phase 3 N=40 Patient Computer Dialog in Primary Care
Patient Computer Dialog
Primary: Patient Post Medical History Assessment Questionnaire — 8.4; 8.3 units on a scale
Phase 3 N=303 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
ADHD · Substance Abuse
Primary: ADHD Severity — -20.6; -21.8 units on a scale
Phase 2 N=34 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Thrombocytopenia · Neutropenia · Lymphopenia
Primary: Chemotherapy Cycles During Which the Platelet Count Measures Below 50,000/mm3 — 20.0; 11.7; 21.5 Percentage of cycles
N/A N=43 Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Phase 2 N=60 Ranibizumab and Reduced Fluence PDT for AMD
Macular Degeneration
Primary: The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months. — 22; 14 percentage of participants
Phase 3 N=192 Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants
Vitamin D Deficiency
Primary: Maternal Serum and Neonatal Serum 25-hydroxyvitamin D Measurement — 21.5; 20.5; 19.6; 40.7 nmol/L
Phase 4 N=58 Study of the Insomnia in Patients With Low Back Pain
Primary Insomnia
Primary: Mean Subjective Sleep Diary Derived Total Sleep Time (TST) — 316.96; 380.45; 403.47; 375.56 Minutes
Phase 4 N=419 Inner-City Anti-IgE Therapy for Asthma
Asthma
Primary: Maximum Number of Asthma Symptom Days — 1.48; 1.96 Days — p=<0.001
Phase 1 N=20 A Smoking Cessation Treatment for Adult Women
Nicotine Dependence
Primary: Point-prevalence Smoking Abstinence Assessed at the End of the Trial and Measured by Self-report and Confirmed by Carbon Monoxide Levels — 4; 1 participants